checkAd

     132  0 Kommentare Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations - Seite 3

    Media Contact:
    Mary Carmichael
    Ten Bridge Communications
    mary@tenbridgecommunications.com
    617-413-3543

    Investor Contact:
    investors@prevailtherapeutics.com

    Lesen Sie auch



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations - Seite 3 Company Will Present at Cowen Healthcare Conference TodayNEW YORK, March 03, 2020 (GLOBE NEWSWIRE) - Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients …